Aim: Decreased cystatin C increases proteolytic effects of cathepsin contributing to plaque rupture. We aimed to investigate the association of cystatin C levels with in-hospital and post-discharge cardiac events in patients with acute myocardial infarction (AMI). Material and Method: We included 85 patients with AMI. Patients with cancer, systemic diseases, increased creatinine, active infection or aortic aneurysm were excluded. Demographic data, laboratory and echocardiographic parameters were analyzed. Serum cystatin C levels were measured in before coronary angiography. Results: Non-ST elevation myocardial infarction was determined in 32.94% of the patients. There were no differences between the normal and high cystatin C groups in terms of gender, diagnosis, obesity, hypertension, hyperlipidemia, cigarette smoking, Killip classification, preference of primary percutaneous coronary intervention or thrombolytic therapy, frequencies of culprit coronary arteries or the number of obstructed arteries. Diabetes mellitus was more frequent in the high cystatin C group. Complication rates after AMI were similar in both the normal and high cystatin C groups on the 5th day and the 12th month. Mean age was higher in the high cystatin C group. ESR, low density lipoprotein (LDL) and total cholesterol were found to be significantly higher in the high cystatin C group. The optimum cut-off values for ESR, LDL and total cholesterol were 11, 88.6, and 161.5, respectively; diagnostic accuracies were adequate. Discussion: The results of the study showed that ESR, LDL and total cholesterol were higher in high cystatin C group, but complications were similar in both groups. We concluded that cystatin C was not a predictor for post-AMI complications at 12th month.
Introduction Atherosclerotic heart disease (ASHD) is one of the most important causes of morbidity and mortality worldwide. Data indicate that ASHD will have a ratio of 33% in all-cause mortality in 2020 [1, 2] . In Turkey, the TEKHARF study reported that the prevalence of coronary artery disease (CAD) was 14% in the 60 -69 years age group [3] . Therefore, it is crucial to understand the physiopathology of ASHD.
In angiographic evaluation of patients before and after acute myocardial infarction (AMI), the lesions causing acute thrombosis and obstruction of the vessel lumen have been shown to be mostly a non-critical stenosis due to atheromatous plaques [4] [5] [6] [7] . It is accepted that acute cardiovascular events result from the rupture of vulnerable plaques and contact of prothrombotic material in plaque with blood. New molecules have been detected that are involved in the formation of atheromatous plaques or the development of complications. These new molecules could be new therapeutic targets in the management of AMI and other acute cardiovascular events. One of these molecules is cystatin C [8, 9] . Several studies have suggested that increased cystatin C is directly related to atherosclerosis [10] . A strong fibrous cap is an important factor contributing to the stability of atheromatous plaque. Unstable plaques are vulnerable to damage at the "shoulder" point. Inflammatory cells at this point secrete proteolytic enzymes destroying the collagenous matrix of the fibrous cap. Cathepsins are the inhibitors of these enzymes, and the most important of these is cystatin C. It has been thought that inflammatory cytokines stimulate the production of cathepsins, and therefore increased levels of cystatin C may indicate counterbalancing activity. Several studies have shown that decreased levels of cystatin C have been found in atheromatous plaques, although this association has not been well studied in patients with AMI [8, 9, 11] . The aim of this study was to investigate the plasma levels of cystatin C in patients with AMI and to evaluate the association of cystatin C levels with in-hospital and post-discharge cardiac complications.
Material and Method

Study Design
The study included a total of 85 patients referred to our clinics who were diagnosed with AMI. Both patients with ST elevation myocardial infarction (STEMI) and Non-ST elevation myocardial infarction (NSTEMI) undergoing primary percutaneous coronary intervention (PCI) or thrombolytic therapy were included in the study. Patients with STEMI were also sub-grouped as anterior or inferior AMI. Any patients with known cancer, active infection, aortic aneurysms or increased creatinine levels (>1.3mg/ dL) were excluded from the study. Demographic data, hematological and biochemical parameters were recorded and analyzed. Complete blood count was measured with an automated counter (Sysmex KX 21N andCobas Integra). Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and lipids were also measured. Due to the initial clinical table of AMI, troponin-I (TnI) and creatine kinase-MB (CK-MB) were measured in all patients. Ejection fraction of left ventricle (EF), left atrium diameter (LA), left ventricle end diastolic diameter (LVEDd), left ventricle end systolic diameter (LVESd), diameters of interventricular septum (IVS) and posterior wall (PW) were measured using echocardiographic evaluation.The patients were followed up for 12 months to observe complications. Complications were defined as mechanical complications, restenosis and death. Cystatin C levels >1.3mg/L were accepted as high.
Cystatin C measurement
Blood samples were drawn before coronary angiography. The samples were collected in tubes withoutEDTA, and were frozen at -70˚C after separation of the plasma. Plasma cystatin C was measured using the immunonephelometric method with a commercial kit (Dade Behiing N Latex Cystatin C assay) and the Behring BN ProSpec II device (Dade Behring Diagnostics). The immunonephelometric method for cystatin C is a fast, safe and automated method. The reliability of this method has been verified in several studies and the "Dade Behiing N Latex CystatinC assay" has been approved by the FDA [12] [13] [14] [15] . In this method, polystyrene particles are coated with specific antibodies against human cystatin C. These polystyrene particles are then aggregated with a sample containing cystatin C. The light passing through these aggregates will distribute light bundles according to the cystatin C concentration. For this purpose, a suspension of polystyrene particles coated with anti-human cystatin C antibodies obtained from rabbits was used. 
Statistical analysis
Results
There were no differences between the normal and high cystatin C groups in terms of gender, diagnosis, obesity, hypertension (HT), hyperlipidemia, or cigarette smoking. Diabetes mellitus (DM) was more frequent in the high cystatin C group (p=0.008, Odds Ratio=0.67, 95% confidence interval). No difference was determined between the groups according to the Killip classification (Table 1) . There were no differences between the normal and high cystatin C groups in terms of preference of primary PCI or thrombolytic therapy. The frequencies of culprit coronary arteries were similar in both groups, as was the number of obstructed coronary arteries (Table 2) . No difference was determined between the normal and high cystatin C groups in respect of the presence of complications on both Day 5 and at the end of the 12thmonth (Table 3) . Mean age was observed to be higher in the high cystatin C group (60.02 ± 11.83 years vs 51.65 ± 14.21 years, p=0.026). Mean height, hematocrit, LVEDd, LVESd, IVS, PW and LA diameter values were similar in both groups (Table 4) . ESR, low density lipoprotein (LDL) and total cholesterol were found to be significantly higher in the high cystatin C group (p=0.037, p=0.017, p=0.010; respectively). Body weight, body mass index (BMI), systolic and diastolic blood pressure, pulse, white blood cell (WBC), platelet (PLT), CRP, blood urea nitrogen (BUN), creatinine (Cre), ALT, AST, CK-MB, TnI, high density lipoprotein (HDL), triglyceride (TG) and EF values were similar in both groups ( Table 5 ).
The optimum cut-off values for ESR, LDL and total cholesterol were 11, 88.6, and 161.5, respectively, as identified by ROC. The area under the curve (AUC) with ESR used to detect high cystatin C was 0.685±0.075 (p=0.015; sensitivity 0.600, specificity 0.750) and diagnostic accuracy was adequate ( Figure 1 ). The AUC with LDL used to detect high cystatin C was 0.683±0.072 (p=0.016; sensitivity 0.855, specificity 0.500) and diagnostic accuracy was adequate ( Figure 2 ). The AUC with total cholesterol used to detect high cystatin C was 0.692±0.076 (p=0.011; sensitivity 0.873, specificity 0.500) and diagnostic accuracy was adequate ( Figure 3 ) (Table 6 ). 
Discussion
The mean age of the patients was observed to be higher in the high cystatin C group. Height and body weight did not differ between the groups. The distributions of gender, type of myocardial infarction, frequency of obesity, hyperlipidemia, hypertension 
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Postmyocardial infaction complication associated with cystatin C and cigarette smoking were similar in both groups. No differences were found between the groups in terms of the number of patients in different Killip classes. The frequency of DM was found to be higher in the high cystatin C group. No differences were found between the groups in terms of type or number of vessels occluded, application of fibrinolytic or primary PCI therapy. Echocardiographic results were similar in both groups. Complications, both on the 5thday and at the end of the 12th month were determined at similar frequencies in both groups. ESR, LDL and total cholesterol values were significantly higher in the high cystatin C group. There were no differences between the groups in respect of hematological and biochemical parameters. Inflammatory cells secrete proteolytic enzymes which destroy the collagenous matrix of the fibrous cap. Cystatin C is one of the most important inhibitors of proteolytic enzymes. Hence, it regulates inflammatory activity and contributes to the formation of balance between production and destruction of the extracellular collagenous matrix [16] . Cystatin C is produced by all nucleated cellssuch as cardiomyocytes. Ischemia promotes the production of cystatin C, and cystatin C modulates vascular inflammatory activity. Therefore, it might be associated with the natural course of atheromatous plaque [17] . Gu et al showed that cystatin C was higher in patients with acute coronary syndrome than in those with stable angina pectoris, in a study using intravascular ultrasonography [18] . It was also reported that cystatin C was correlated with plaque area. Akgul et al. investigated the association of cystatin C with inhospital and post-discharge complications in 475 patients with STEMI who had undergone primary PCI [19] . In that study, similar to the current study findings and another study by Ristiniemi, the mean age was higher in the high cystatin C group [20] . Older patients with coronary artery disease can be assumed to have an increased inflammatory burden, DM associated with increased age, and increased malnutrition. The increased inflammatory state may explain the increased mean age in the high cystatin C group. As renal function decreases with increasing age [21] , this could also explain the older age in the high cystatin C groups. In a study by Akgul et al. a history of DM was found to be more prevalent in the high cystatin C group similar to the current study. DM is known to be an accepted traditional risk factor for coronary artery disease, so these results were anticipated. Some studies have shown that cystatin C level was related not only to cardiovascular disease but also to type 2 DM [22] . However, in some studies, the frequency of DM was similar in both groups [20] . In one study, 660 very elderly patients (>80 years) undergoing coronary angiography for acute coronary syndrome were investigated to detect the prognostic impact of cystatin C [23] .
Patients were separated into two groups according to the presence of DM. Over a mean follow-up period of 28 months, Cystatin C was found to be significantly higher in the diabetic group. Survival was significantly lower in diabetics and mortality was higher. Plasma cystatin C concentration was reported to be an independent predictor for adverse cardiac events in the diabetic group, with a cut-off value for mortality in diabetics of 1.605. In the current study, LDL and total cholesterol were found to be higher in the high cystatin C group, and creatinine and hemoglobin were similar in both groups. However, in another study, creatinine was higher, and hemoglobin and LDL were lower in high cystatin C groups, while other lipids were similar [19] . Elevated creatinine may be a confounder for cystatin C to be a predictor.
In the same study, the distribution of culprit coronary arteries and the number of obstructed vessels were not different between the 2 groups, which was a similar finding to the current study. In that previous study, both in-hospital and 1-month major adverse cardiac events, both in-hospital and 1-month advanced heart failure, cardiogenic shock, resuscitation, intra-aortic balloon pump use, atrial fibrillation, transient pacemaker use, gastrointestinal hemorrhage were detected at higher rates in the high cystatin C group. The in-hospital and 1-month cardiovascular mortality rates were found to be increased in patients with higher cystatin C compared to low cystatin C (9.4% vs 1.6%, p<0.001; 14.5% vs 2.2%, p<0.001; respectively). High cystatin C was found to be a strong predictor for mortality (OR=5.3, p=0.02). In contrast to the current study, Killip scoring and history of HT were higher in the high cystatin C group. This difference could have resulted from the inclusion of patients with STEMI only, in that study. A Killip score >1 was also determined as an independent predictor of mortality in that study. Similarly, in a study by Ristiniemi, mortality risk increased with increasing cystatin C levels, with a hazard ratio of cystatin C for mortality of 2.19 [20] . Two other studies also investigated the predictive role of cystatin C in patients with STEMI [24, 25] . Ichimoto et al found that high cystatin C was associated with hospitalization for heart failure, and Silva et al showed that patients who developed cardiogenic shock had higher cystatin C levels. Ristiniemi et al included 245 patients with NSTEMI and followed up them 1 year. Increased serum cystatin C was found to be an independent predictor of all-cause mortality and AMI after adjustments for other factors. Creatinine was not an independent factor for adverse outcomes and it can be concluded that cystatin C may not be affected by multiple confounders [20] . In the current study, cardiac biomarkers were found to be similar in the high and normal cystatin C groups. In a study by Ristiniemi, again TnI levels were found to be similar in both groups [20] . Due to the nature of the patient groups included in the current study, the similarity was expected. In a previous study investigating major adverse cardiac events, 160 patients with acute coronary syndrome were evaluated. Cardiac events were determined at a higher rate in the high cystatin C group, and cystatin C was found to be the most important parameter associated with major cardiac events [26] . Taglieri et al. evaluated 525 patients with NSTEMI in the "Systemic Inflammation Evaluation in patients with NSTE-ACS" (SIESTA) study [27] . Patients were subgrouped according to the cystatin C levels. The higher cystatin C groups were associated with cardiac events at 1-year follow-up, although serum creatinine was not a predictor for end point. In a study including 726 patients with NSTEMI, cystatin C was again found to be independently associated with mortality but not with the risk of subsequent AMI [28] . Cystatin C is eliminated mainly by glomerular filtration, neither secreted nor reabsorbed by tubules [29] . The cystatin C level is not influenced by age, muscle mass, exercise, sex or diet [30, 31] . It has been shown to be superior in evaluating renal function compared to creatinine [32] [33] [34] [35] . Several studies have shown the inverse relationship between decreased renal function and cardiovascular outcomes [36] [37] [38] . Cystatin C has also been shown to be a superior marker in the prediction of preclinical kidney disease compared to creatinine [32] . When investigating the role of cystatin C in cardiovascular mortality in patients with AMI, the results should be adjusted for potential confounders such as increased creatinine level. After adjustment for creatinine, Akgul et al and Silva et al found cystatin C to be an independent factor in the development of cardiovascular mortality after AMI [19, 25] . Especially in the elderly, cystatin C shows higher sensitivity and detects minor impairments compared to creatinine and it increases more steeply than creatinine [39, 40] . Minor renal dysfunction may also be of important clinical significance. From this aspect, the association of cystatin C with mortality can be expected to be more prominent compared to creatinine, as has been shown in a previous study [41] . Sanchis et al. investigated the predictors of frailty in 342 patients suffering from acute coronary syndrome, and cystatin C >1.2mg/L was detected as one of the biomarkers predicting frailty [42] .
To eliminate the confounding effect of creatinine, some studies have been designed to include a number of patients with glomerular filtration rate >60mL/min [43] . Abid et al. investigated 127 patients without chronic kidney disease, undergoing coronary angiography for acute coronary syndrome [43] . Cystatin C was found to be associated with the severity of coronary artery disease both according to the number of culprit vessels and the Gensini score. The patients were followed up for an average of 10 months, and cystatin C was associated with both unfavorable outcomes and cardiovascular mortality. Sun et al. investigated 605 patients with acute coronary syndrome undergoing successful PCI [44] . Patients were separated into groups according to cystatin C levels. In afollow-up period of at least 12 months, mortality, non-fatal myocardial infarction, revascularization, and heart failure rates were determined to be higher in the high cystatin C groups. Cystatin C elevation was shown as an independent predictor of major adverse cardiac events, and survival was lower in higher cystatin C groups. EF was lower in patients with major adverse cardiac events, and was a predictor for cardiac events. In that study, elevated cystatin C was found to be a predictor for cardiac events in contrast to the current study results. Sun et al. followed up patients for at least 12 months and the predictive value of cystatin C even in the 12th month indicated cystatin C as a long-term marker in patients with acute coronary syndrome. The current study follow-up was relatively shorter. In addition, the patients included in that previous study were patients with both AMI and unstable angina pectoris, who underwent only successful PCI defined as TIMI (thrombolysis in myocardial infarction) III flow after intervention. In the current study, patients with unstable angina pectoris were not included, although patients undergoing both PCI and thrombolytic therapy were included. In the above-mentioned study, an unsuccessful procedure was found to be an independent predictor for cardiac events [19] . Therefore, inclusion of both patients with successful and unsuccessful interventions may cause a confounding effect, but provide exact results. One of the limitations of the current study was the small study population. More patients with acute coronary syndrome could have been included. Furthermore, other than for cystatin C, the patients could not be separated into subgroups as those with STEMI or NSTEMI. The results were analyzed of patients undergoing thrombolytic therapy and primary PCI. Further subgrouping according to the therapy applied could have been useful but would have required a larger sample. Patients were followed up for 12 months. Several studies analyzing long-term complications post AMI have been published in literature.
In conclusion, the results of this study showed that post-AMI complications both at the 5th and 12th month were found at similar frequencies in both the high and normal cystatin C groups. ESR, LDL and total cholesterol values were significantly higher in the high cystatin C group. Further investigations are necessary to show the association of these parameters with cystatin C. 
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